These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8738669)

  • 1. The influence of the immunosuppressants OKT3 and ATG on immunological parameters.
    Neumann MC; Müller TF; Sprenger H; Gemsa D; Lange H
    Clin Nephrol; 1996 May; 45(5):345-8. PubMed ID: 8738669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of polyclonal anti-T-lymphocyte antibodies (ATG) in the kidney transplantation].
    Nikolovski M; Kotsev Iu; Dimitrov S; Nikolova M; Panchev P
    Khirurgiia (Sofiia); 2004; 60(4-5):42-5. PubMed ID: 16042064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
    Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
    Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of TH1/TH2 cytokines in kidney allograft rejection.
    Karczewski J; Karczewski M; Glyda M; Wiktorowicz K
    Transplant Proc; 2008 Dec; 40(10):3390-2. PubMed ID: 19100396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
    Baldi A; Malaise J; Mourad M; Squifflet JP
    Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
    [No Abstract]   [Full Text] [Related]  

  • 11. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring immunosuppression following renal transplantation.
    Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
    Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3].
    Müller T; Keuchel M; Schindler S; Steinmetz A; Feiber H; Lange H
    Helv Chir Acta; 1991 Sep; 58(3):271-5. PubMed ID: 1769844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
    Kaiser BA; Palmer JA; Dunn SP; Mochon MA; Bartosh SM; Schulman SL; Polinsky MS; Baluarte HJ
    Child Nephrol Urol; 1991; 11(4):190-2. PubMed ID: 1777898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
    Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
    Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
    Nashan B
    BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.